Eli Lilly said on Friday the U.S. Food and Drug Administration approved its eczema drug for use in adults and children above 12 years old. The drug, which is an injectable medicine and branded Ebglyss,

INDIANAPOLIS–The U.S. Food and Drug Administration has approved Eli Lilly’s new treatment for moderate to severe eczema. It’s called Ebglyss. Ebglyss is used as an injection to treat anyone 12 and older who also weighs at least 88 pounds.

Three years after establishing an immunology unit, Eli Lilly has gained its third FDA approval in the specialty area as the U.S. regulator has signed off on IL-13 inhibitor Ebglyss to treat atopic dermatitis (AD).

The U.S. Food and Drug Administration has approved Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 years and older with moderate-to-severe atopic dermatitis. The targeted interleukin-13 inhibitor is administered via a 250-mg/2 mL injection with or without topical corticosteroids in patients